55897-04-6

Basic information

• Product Name: (Ethoxycarbonyl)methanesulfonamide
• Synonyms: (Ethoxycarbonyl)methanesulfonamide
• CAS NO: 55897-04-6
• Molecular Weight: 167.186
• Mol File: 55897-04-6.mol

Chemical Properties

• Melting Point: 67-68 °C
• Boiling Point: 299.1±42.0 °C(Predicted)
• Density: 1.361±0.06 g/cm3(Predicted)
• CAS DataBase Reference: (Ethoxycarbonyl)methanesulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: (Ethoxycarbonyl)methanesulfonamide(55897-04-6)
• EPA Substance Registry System: (Ethoxycarbonyl)methanesulfonamide(55897-04-6)

Safety Data

• Hazardous Substances Data: 55897-04-6(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Synthesis:
ECM is utilized as a reagent in the synthesis of a wide array of organic and pharmaceutical compounds. Its ability to act as a masked source of amines and its stability under various reaction conditions make it a valuable component in the development of new medications.
Used in Drug Development:
(Ethoxycarbonyl)methanesulfonamide is also explored for its potential as a drug moiety in the treatment of various diseases. Its unique properties and reactivity contribute to the design and synthesis of novel therapeutic agents.
Used in Chemical Research:
ECM's versatility and stability make it a useful compound in chemical research, where it can be employed to study various reaction mechanisms and to develop new synthetic methods.
Used in Synthesis of Precursors:
As a precursor in the synthesis of pharmaceuticals, ECM plays a crucial role in the production of various drugs, contributing to the advancement of the pharmaceutical industry.

Upstream product

• 4025-78-9 chlorosulfonyl-acetic acid 
• 64-17-5 ethanol 
• 55895-40-4 sulfamoyl-acetic acid amide 
• 55896-93-0 ethyl 2-(chlorosulfonyl)acetate 

Downstream Products

• 67541-98-4 Hydrazinocarbonyl-methanesulfonamide 
• 635313-85-8 ((S)-2-Benzyloxycarbonylamino-pentanoylsulfamoyl)-acetic acid ethyl ester 
• 635313-82-5 ((S)-2-Benzyloxycarbonylamino-propionylsulfamoyl)-acetic acid ethyl ester 
• 635313-79-0 ((S)-2-Benzyloxycarbonylamino-3-methyl-butyrylsulfamoyl)-acetic acid ethyl ester 
• 635313-83-6 ((S)-2-Benzyloxycarbonylamino-4-methylsulfanyl-butyrylsulfamoyl)-acetic acid ethyl ester 
• 635313-80-3 ((2S,3R)-2-Benzyloxycarbonylamino-3-methyl-pentanoylsulfamoyl)-acetic acid ethyl ester 
• 635313-77-8 ((2S,3S)-2-Benzyloxycarbonylamino-3-methyl-pentanoylsulfamoyl)-acetic acid ethyl ester 
• 635313-81-4 ((2R,3R)-2-Benzyloxycarbonylamino-3-methyl-pentanoylsulfamoyl)-acetic acid ethyl ester 
• 635313-84-7 ((S)-2-Benzyloxycarbonylamino-hexanoylsulfamoyl)-acetic acid ethyl ester 
• 635313-78-9 ((S)-2-Benzyloxycarbonylamino-4-methyl-pentanoylsulfamoyl)-acetic acid ethyl ester 

Relevant articles and documents

Investigation of 3-sulfamoyl coumarins against cancer-related IX and XII isoforms of human carbonic anhydrase as well as cancer cells leads to the discovery of 2-oxo-2H-benzo[h]chromene-3-sulfonamide – A new caspase-activating proapoptotic agent

Herein we report the synthesis of a set of seventeen 3-sulfonamide substituted coumarin derivatives. Prepared compounds were tested in vitro for inhibition of four physiologically relevant isoforms of the metalloenzyme human carbonic anhydrase (hCA, EC 4.2.1.1). Several coumarin sulfonamides displayed low nanomolar KI values against therapeutically relevant hCA II, IX, and XII, whereas they did not potently inhibit hCA I. Some of these compounds exerted a concentration-dependent antiproliferative action toward RT4 human bladder cancer and especially A431 human epidermoid carcinoma cell lines. In the meantime, the viability of non-tumorigenic hTERT immortalized human foreskin fibroblast cell line Bj-5ta was not significantly affected by the obtained derivatives. Interestingly, compound 10q (2-oxo-2H-benzo [h]chromene-3-sulfonamide) showed a profound and selective dose-dependent inhibition of A431 cell growth with low nanomolar IC50 values. We demonstrated that 10q possessed a concentration-dependent apoptosis induction activity associated with caspase 3/7 activation in cancer cells. As carbonic anhydrase isoforms in question were not potently inhibited by this compound, its antiproliferative effects likely involve other mechanisms, such as DNA intercalation. Compound 10q clearly represents a viable lead for further development of new-generation anticancer agents.

HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC CONDITIONS AND DISORDERS

The invention relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): (I), wherein L1, A, X1, X2, R1, R2, and R3 are described herein.

Direct Synthesis of Trisubstituted Isothiazole 1,1-Dioxides. Regioselective Substitution Reactions at C-3 and C-4

A direct synthesis of trisubstituted mononuclear isothiazole 1,1-dioxides (isothiazole sulfones) has been achieved.Regioselective nucleophilic substitutions of 3,4-dichloro- and 4-chloro-3-ethoxy-5-(ethoxycarbonyl)isothiazole 1,1-dioxide with alcohol, amines, and N-(trimethylsilyl)amines at the C-3 and C-4 positions were elucidated.The crystal structure of 3-ethoxy-4-amino-5-(ethoxycarbonyl)isothiazole 1,1-dioxide was determined to characterize the ring system and establish regioselectivity of ammonolysis.The 13C spectra of several isothiazole sulfones have been obtained and the chemical shifts assigned and correlated with calculated CNDO/2 charge densities.